ArticleFrontiers in oncology2026
Component-based CT radiomics for preoperative differentiation of well-differentiated and dedifferentiated retroperitoneal liposarcoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Preoperative distinction between well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) remains difficult on conventional imaging. We evaluated whether CT attenuation-defined regional radiomics provides additional discriminatory information beyond whole-tumor radiomics and simple quantitative CT measurements. Methods: This retrospective study included 97 patients with surgically confirmed retroperitoneal liposarcoma (57 WDLPS and 40 DDLPS) who underwent preoperative contrast-enhanced CT. Radiomics features were extracted from the whole tumor (W), CT-defined fat-attenuation (F) and soft-tissue-attenuation (S) subregions, and a 3-mm peritumoral region (R). Six prespecified feature sets (W, F, S, WF, WFS, and WFR) were modeled with L1-regularized logistic regression using nested cross-validation. Clinical and quantitative CT benchmark models were also evaluated, and the WF feature set was further compared across logistic regression, support vector machine, random forest, and XGBoost classifiers. Performance was assessed from held-out out-of-fold predictions. Results: The WF model had the highest pooled out-of-fold AUC among the six regional models (0.864; 95% CI, 0.778-0.940), but adding S or R features did not improve discrimination. The quantitative CT and clinical models achieved AUCs of 0.849 and 0.562, respectively. In a separate 10-times repeated nested cross-validation analysis, the mean fold-wise AUC difference between WF and quantitative CT was 0.023 (95% CI, -0.030 to 0.076; Holm-adjusted P = 0.389), and no pairwise comparison among the six regional models remained significant after Holm correction. When feature-set and classifier selection were repeated within the outer cross-validation loop, the selection-aware AUC was 0.842 (95% CI, 0.748-0.926). Logistic regression had the highest AUC among the four classifiers evaluated with the WF feature set. Whole-tumor mean intensity, fat-subregion run-length non-uniformity normalized, and whole-tumor GLCM correlation were the leading features in the descriptive interpretation analysis. Discussion: CT attenuation-defined regional radiomics was feasible for preoperative WDLPS-DDLPS differentiation, but the WF model did not show a significant advantage over whole-tumor radiomics or segmentation-derived quantitative CT. External validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.